a Department of Pediatrics , Foundation IRCCS Policlinico San Matteo, University of Pavia , Pavia , Italy.
b Pediatric Allergy , IRCCS Istituto Giannina Gaslini , Genoa , Italy.
Expert Rev Clin Immunol. 2018 Aug;14(8):657-663. doi: 10.1080/1744666X.2018.1504679. Epub 2018 Jul 31.
Allergen immunotherapy represents the only disease-modifying therapy available for immunoglobulin E-mediated diseases such as allergic rhinitis and asthma. Allergen immunotherapy induces allergen tolerance by interfering with the immune-pathogenic mechanisms of the allergic response and is potentially able to provide long-term relief of symptoms of allergic rhinitis and asthma and alter the natural course of allergic diseases. Areas covered: Since allergen immunotherapy (AIT) is actually considered an individualized treatment on patient's clinical and immunological profile, the identification of specific biomarkers, which may guide diagnosis, management, and predict response to AIT treatment in allergic rhinitis (AR) patients, is essential and is currently an active field of research. Expert commentary: The identification and validation of biomarkers of successful AIT for AR is an urgent need to definitively establish the role of AIT as a therapeutic tool of personalized medicine.
变应原免疫疗法代表了唯一可用于治疗免疫球蛋白 E 介导的疾病的疾病修正疗法，如过敏性鼻炎和哮喘。变应原免疫疗法通过干扰过敏反应的免疫发病机制诱导变应原耐受，并有潜力提供过敏性鼻炎和哮喘症状的长期缓解，并改变过敏性疾病的自然病程。涵盖领域：由于变应原免疫疗法（AIT）实际上被认为是根据患者的临床和免疫学特征进行的个体化治疗，因此确定可能指导过敏性鼻炎（AR）患者的诊断、管理和预测 AIT 治疗反应的特定生物标志物至关重要，这是目前一个活跃的研究领域。专家评论：确定和验证 AR 成功 AIT 的生物标志物是当务之急，以明确确立 AIT 作为个性化医学治疗工具的作用。
